Butaprost free acid

Name: Butaprost free acid
Brand: MedChemExpress
SKU: HY-120973
Rating: 5.0 (2 reviews)

Cat. No.: HY-120973: FAQs
Data Sheet Handling Instructions Technical Support

Butaprost free acid is a selective prostaglandin E receptor (EP2) agonist with an EC₅₀ of 33 nM and a K_i of 2.4 μM for murine EP2 receptor. Butaprost free acid is less activity against murine EP1, EP3 and EP4 receptors. Butaprost free acid attenuates fibrosis by hampering TGF-β/Smad2 signalling.

For research use only. We do not sell to patients.

Butaprost free acid Chemical Structure

CAS No. : 215168-33-5

Size	Price	Stock	Quantity
500 μg		Get quote 3 - 4 weeks 4 - 5 weeks 2 - 3 weeks	Estimated Time of Arrival: December 31

Synthetic products have potential research and development risk.

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 2 publication(s) in Google Scholar

Other Forms of Butaprost free acid:

(S)-Butaprost free acid Get quote
Butaprost Get quote

2 Publications Citing Use of MCE Butaprost free acid

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

View All Prostaglandin Receptor Isoform Specific Products:

View All Isoforms

DP EP FP IP TXA₂/TP TXB₂

Biological Activity
Purity & Documentation
References
Customer Review

Description

In Vitro

Butaprost (1-100 nM; 0.5-24 hours) free acid induces about a five-fold upregulation of Nur77 mRNA expression in hEP2-HEK293/EBNA cells in a dose- and time-dependent. Butaprost free acid upregulated Nur77 gene expression through the PKC pathway^[1].
Butaprost (50 μM; 24 hours) free acid reduces TGF-β-induced fibronectin (FN) expression, Smad2 phosphorylation and epithelial-mesenchymal transition in Madin-Darby Canine Kidney (MDCK) cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:	HEK 293/EBNA cells stably expressing the human EP2 receptor (hEP2-HEK 293/EBNA cells).
Concentration:	1 nM, 10 nM, 100 nM
Incubation Time:	0.5 hours, 1 hours, 6 hours, 24 hours
Result:	Induced about a five-fold upregulation of Nur77 mRNA expression in hEP2-HEK293/EBNA cells.

In Vivo

Butaprost (1-4 mg/kg; intraperitoneal injection; twice daily; for 7 days) free acid treatment attenuates the development of fibrosis in mice that underwent unilateral ureteral obstruction surgery, as illustrated by a reduction in the gene and protein expression of α-smooth muscle actin, fibronectin and collagen 1A1^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male C57BL/6 mice (8 weeks of age; 21 g) bearing unilateral ureteral obstruction surgery^[2].
Dosage:	1 mg/kg, 2 mg/kg, 4 mg/kg
Administration:	Intraperitoneal injection; twice daily; for 7 days
Result:	Attenuated the development of fibrosis in mice that underwent unilateral ureteral obstruction surgery.

Molecular Weight

394.54

Formula

C₂₃H₃₈O₅

CAS No.

215168-33-5

SMILES

O=C(O)CCCCCC[C@@H]1[C@@H](/C=C/C[C@@H](O)C2(CCC)CCC2)[C@H](O)CC1=O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Handling Instructions (2659 KB)

References

[1]. Yanbin Liang, et al. Upregulation of orphan nuclear receptor Nur77 following PGF(2alpha), Bimatoprost, and Butaprost treatments. Essential role of a protein kinase C pathway involved in EP(2) receptor activated Nur77 gene transcription. Br J Pharmacol. 2004 Jun;142(4):737-48. [Content Brief]

[2]. Michael Schou Jensen, et al. Activation of the prostaglandin E 2 EP 2 receptor attenuates renal fibrosis in unilateral ureteral obstructed mice and human kidney slices. Acta Physiol (Oxf). 2019 Sep;227(1):e13291. [Content Brief]

[3]. K Tani, et al. Design and synthesis of a highly selective EP2-receptor agonist. Bioorg Med Chem Lett. 2001 Aug 6;11(15):2025-8. [Content Brief]